TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).

Dmytro Trukhin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.